

post-natal growth in disorders characterized by aberrant angiogenesis such as persistent hyperplastic primary vitreous. This study has shown that anti-angiogenic agents capable of inducing FGR can result in concomitant microphthalmia, providing evidence for contraindication of use of these agents during pregnancy.

ACKNOWLEDGMENTS

The authors would like to thank Professor T. Mayhew for useful discussions and guidance on stereology (Biomedical Sciences, University of Nottingham, UK), Mrs. M. Mitchell for animal care, and Mr. T. Gray and Mr. P. Hinson (Electron Microscopy Unit, Division of Pathology, Queen's Medical Centre, Nottingham, UK) who kindly assisted with histological techniques.

REFERENCES

1. NIH. <http://www.cancer.gov/cancertopics/factsheet/Therapy/angiogenesis-inhibitors>. 2007.
2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med* 2006; 355:1419-31. [PMID: 17021318]
3. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. *Nature* 1990; 348:555-7. [PMID: 1701033]
4. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. *Proc Natl Acad Sci USA* 1997; 94:6099-103. [PMID: 9177176]
5. Zhang P, Nicholson DE, Bujnicki JM, Su X, Brendle JJ, Ferdig M, Kyle DE, Milhous WK, Chiang PK. Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis. *J Biomed Sci* 2002; 9:34-40. [PMID: 11810023]
6. Soff GA. Angiostatin and angiostatin-related proteins. *Cancer Metastasis Rev* 2000; 19:97-107. [PMID: 11191071]
7. Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC, Soff GA. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. *Cancer Res* 1996; 56:4887-90. [PMID: 8895739]
8. Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D, Presta M, Albini A, Cassatella MA. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. *J Immunol* 2002; 168:5798-804. [PMID: 12023382]
9. Albini A, Brigati C, Ventura A, Lorusso G, Pinter M, Morini M, Mancino A, Sica A, Noonan DM. Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. *J Transl Med* 2009; 7:5. [PMID: 19144161]
10. Kang HT, Bang WK, Yu YG. Identification and characterization of a novel angiostatin-binding protein by the display cloning method. *J Biochem Mol Biol* 2004; 37:159-66. [PMID: 15469691]
11. Youn MR, Park MH, Choi CK, Ahn BC, Kim HY, Kang SS, Hong YK, Joe YA, Kim JS, You WK, Lee HS, Chung SI, Chang SI. Direct binding of recombinant plasminogen kringle 1-3 to angiogenin inhibits angiogenin-induced angiogenesis in the chick embryo CAM. *Biochem Biophys Res Commun* 2006; 343:917-23. [PMID: 16564503]
12. Hanford HA, Wong CA, Kassan H, Cundiff DL, Chandel N, Underwood S, Mitchell CA, Soff GA. Angiostatin(4,5)-mediated apoptosis of vascular endothelial cells. *Cancer Res* 2003; 63:4275-80. [PMID: 12874037]
13. Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BK, Wu Z, Grau GE, Shing Y, Soff GA, Bouck N, Pepper MS. Multiple forms of angiostatin induce apoptosis in endothelial cells. *Blood* 1998; 92:4730-41. [PMID: 9845539]
14. Sharma MR, Rothman V, Tuszyński GP, Sharma MC. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action. *Exp Mol Pathol* 2006; 81:136-45. [PMID: 16643891]
15. Goretzki L, Lombardo CR, Stallcup WB. Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen). *J Biol Chem* 2000; 275:28625-33. [PMID: 10889192]
16. Wajih N, Sane DC. Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. *Blood* 2003; 101:1857-63. [PMID: 12406896]
17. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. *J Cell Biol* 2001; 152:1247-54. [PMID: 11257124]
18. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW, Pizzo SV. Angiostatin binds ATP synthase on the surface of human endothelial cells. *Proc Natl Acad Sci USA* 1999; 96:2811-6. [PMID: 10077593]
19. Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta [3] in endothelial cells. *J Biol Chem* 2001; 276:39562-8. [PMID: 11514539]
20. Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. *J Cell Biochem* 2005; 96:242-61. [PMID: 16094651]
21. Klauber N, Rohan RM, Flynn E, D'Amato RJ. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. *Nat Med* 1997; 3:443-6. [PMID: 9095179]
22. Rutland CS, Mukhopadhyay M, Underwood S, Clyde N, Mayhew TM, Mitchell CA. Induction of Intrauterine Growth Restriction by Reducing Placental Vascular Growth with the Angiostatin TNP-470. *Biol Reprod* 2005; 73:1164-73. [PMID: 16079307]
23. Atkinson SD, Rutland CS, Mukhopadhyay M, Yin TT, Loughna P, Soff GA, Mayhew TM, Mitchell CA. Angiostatin is associated with perturbed placental vascular growth and fetal growth restriction (FGR). *British Microcirculation Society Meeting; 2007 April 2-3; Belfast (UK)*.
24. Gedeon C, Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. *Placenta* 2006; 27:861-8. [PMID: 16313957]

25. Rout UK. Valproate, thalidomide and ethyl alcohol alter the migration of HTR-8/SVneo cells. *Reprod Biol Endocrinol* 2006; 4:44. [PMID: 16923192]
26. Hallene KL, Oby E, Lee BJ, Santaguida S, Bassanini S, Cipolla M, Marchi N, Hossain M, Battaglia G, Janigro D. Prenatal exposure to thalidomide, altered vasculogenesis, and CNS malformations. *Neuroscience* 2006; 142:267-83. [PMID: 16859833]
27. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. *Nat Rev Cancer* 2005; 5:423-35. [PMID: 15928673]
28. Sathornsumetee S, Rich JN. New approaches to primary brain tumor treatment. *Anticancer Drugs* 2006; 17:1003-16. [PMID: 17001172]
29. Newton HB. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors. *Curr Opin Investig Drugs* 2007; 8:1009-21. [PMID: 18058572]
30. Loeliger M, Briscoe T, Lambert G, Caddy J, Rehn A, Dieni S, Rees S. Chronic placental insufficiency affects retinal development in the guinea pig. *Invest Ophthalmol Vis Sci* 2004; 45:2361-7. [PMID: 15223818]
31. Loeliger M, Duncan J, Louey S, Cock M, Harding R, Rees S. Fetal growth restriction induced by chronic placental insufficiency has long-term effects on the retina but not the optic nerve. *Invest Ophthalmol Vis Sci* 2005; 46:3300-8. [PMID: 16123433]
32. Loeliger M, Louey S, Cock ML, Harding R, Rees SM. Chronic placental insufficiency and foetal growth restriction lead to long-term effects on postnatal retinal structure. *Clin Experiment Ophthalmol* 2003; 31:250-3. [PMID: 12786778]
33. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. *J Neurosci* 1995; 15:4738-47. [PMID: 7623107]
34. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. *Nat Med* 1995; 1:1024-8. [PMID: 7489357]
35. Mitchell CA, Rutland CS, Walker M, Nasir M, Foss AJ, Stewart C, Gerhardt H, Konerding MA, Risau W, Drexler HC. Unique vascular phenotypes following over-expression of individual VEGFA isoforms from the developing lens. *Angiogenesis* 2006; 9:209-24. [PMID: 17109192]
36. Ash JD, Overbeek PA. Lens-specific VEGF-A expression induces angioblast migration and proliferation and stimulates angiogenic remodeling. *Dev Biol* 2000; 223:383-98. [PMID: 10882523]
37. Ahmed MH, Konno H, Nahar L, Tanaka T, Naito Y, Nakamura S, Baba S. The angiogenesis inhibitor TNP-470 (AGM-1470) improves long-term survival of rats with liver metastasis. *J Surg Res* 1996; 64:35-41. [PMID: 8806471]
38. Koyanagi S, Nakagawa H, Kuramoto Y, Ohdo S, Soeda S, Shimeno H. Optimizing the dosing schedule of TNP-470 [O-(chloroacetyl-carbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies. *J Pharmacol Exp Ther* 2003; 304:669-74. [PMID: 12538820]
39. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. *Clin Cancer Res* 2001; 7:977-84. [PMID: 11309349]
40. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR. Combined effects of angiostatin and ionizing radiation in antitumour therapy. *Nature* 1998; 394:287-91. [PMID: 9685160]
41. Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. *J Microsc* 1987; 147:229-63. [PMID: 3430576]
42. Mayhew TM, Burton GJ. Methodological problems in placental morphometry: apology for the use of stereology based on sound sampling practice. *Placenta* 1988; 9:565-81. [PMID: 3070535]
43. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. *Int J Dev Biol* 2004; 48:1045-58. [PMID: 15558494]
44. Rutland CS, Mitchell CA, Nasir M, Konerding MA, Drexler HC. Microphthalmia, persistent hyperplastic hyaloid vasculature and lens anomalies following overexpression of VEGF-A188 from the alphaA-crystallin promoter. *Mol Vis* 2007; 13:47-56. [PMID: 17277743]
45. Gervaz P, Fontollet C. Therapeutic potential of the anti-angiogenesis drug TNP-470. *Int J Exp Pathol* 1998; 79:359-62. [PMID: 10319017]
46. Golzio C, Martinovic-Bouriel J, Thomas S, Mougou-Zrelli S, Grattagliano-Bessieres B, Bonniere M, Delahaye S, Munnich A, Encha-Razavi F, Lyonnet S, Vekemans M, Attie-Bitach T, Etchevers HC. Matthew-Wood syndrome is caused by truncating mutations in the retinol-binding protein receptor gene STRA6. *Am J Hum Genet* 2007; 80:1179-87. [PMID: 17503335]
47. Wong JC, Alon N, McKerlie C, Huang JR, Meyn MS, Buchwald M. Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia. *Hum Mol Genet* 2003; 12:2063-76. [PMID: 12913077]
48. Male A, Davies A, Bergbaum A, Keeling J, FitzPatrick D, Mackie Ogilvie C, Berg J. Delineation of an estimated 6.7 MB candidate interval for an anophthalmia gene at 3q26.33-q28 and description of the syndrome associated with visible chromosome deletions of this region. *Eur J Hum Genet* 2002; 10:807-12. [PMID: 12461687]
49. Cain CC, Saul D, Attanasio L, Oehler E, Hamosh A, Blakemore K, Stetten G. Microphthalmia with linear skin defects (MLS) syndrome evaluated by prenatal karyotyping, FISH and array comparative genomic hybridization. *Prenat Diagn* 2007; 27:373-9. [PMID: 17286317]
50. Leung CC. Antiserum to rat visceral yolk sac endoderm induced abnormal embryonic development. *Pediatr Res* 1983; 17:313-8. [PMID: 6343995]
51. Hande MP, Veena K. Teratogenic effect of hyperthermia during early organogenesis period in mice. *Teratog Carcinog Mutagen* 1993; 13:145-50. [PMID: 8105556]
52. Hinzpeter EN, Renz S, Loser H. Eye manifestations of fetal alcohol syndrome. *Klin Monatsbl Augenheilkd* 1992; 200:33-8. [PMID: 1583839]

53. Stromland K. Ocular abnormalities in the fetal alcohol syndrome. *Acta Ophthalmol Suppl* 1985; 171:1-50. [PMID: 2988263]
54. Chan T, Howell R, O'Keefe M, Lanigan B. Ocular manifestations in fetal alcohol syndrome. *Br J Ophthalmol* 1991; 75:524-6. [PMID: 1911652]
55. Pinazo-Duran MD, Renau-Piqueras J, Guerri C. Developmental changes in the optic nerve related to ethanol consumption in pregnant rats: analysis of the ethanol-exposed optic nerve. *Teratology* 1993; 48:305-22. [PMID: 8278930]
56. Pinazo-Duran MD, Renau-Piqueras J, Guerri C, Stromland K. Optic nerve hypoplasia in fetal alcohol syndrome: an update. *Eur J Ophthalmol* 1997; 7:262-70. [PMID: 9352281]
57. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, O'Reilly M, Folkman J. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. *Proc Natl Acad Sci USA* 1998; 95:5579-83. [PMID: 9576925]
58. Cook CS, Nowotny AZ, Sulik KK. Fetal alcohol syndrome. Eye malformations in a mouse model. *Arch Ophthalmol* 1987; 105:1576-81. [PMID: 3675291]
59. Cook CS, Sulik KK. Keratolenticular dysgenesis (Peters' anomaly) as a result of acute embryonic insult during gastrulation. *J Pediatr Ophthalmol Strabismus* 1988; 25:60-6. [PMID: 3162748]
60. el-Hifnawi E, el-Hifnawi A, Frankenberg C, Keeler C. Ultrastructure and regression of the tunica vasculosa lentis in newborn Wistar rats. *Ann Anat* 1994; 176:143-9. [PMID: 8210049]
61. Zhang W, Ito Y, Berlin E, Roberts R, Luan H, Berkowitz BA. Specificity of subnormal deltaPO2 for retinal neovascularization in experimental retinopathy of prematurity. *Invest Ophthalmol Vis Sci* 2003; 44:3551-5. [PMID: 12882806]
62. Goldberg MF. Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. *Am J Ophthalmol* 1997; 124:587-626. [PMID: 9372715]
63. Hittner HM, Hirsch NJ, Rudolph AJ. Assessment of gestational age by examination of the anterior vascular capsule of the lens. *J Pediatr* 1977; 91:455-8. [PMID: 894419]
64. Hittner HM, Gorman WA, Rudolph AJ. Examination of the anterior vascular capsule of the lens: II. Assessment of gestational age in infants small for gestational age. *J Pediatr Ophthalmol Strabismus* 1981; 18:52-4. [PMID: 7195426]
65. Hittner HM, Speer ME, Rudolph AJ. Examination of the anterior vascular capsule of the lens: III. Abnormalities in infants with congenital infection. *J Pediatr Ophthalmol Strabismus* 1981; 18:55-60. [PMID: 6264058]
66. Skapinker R, Rothberg AD. Postnatal regression of the tunica vasculosa lentis. *J Perinatol* 1987; 7:279-81. [PMID: 3505262]
67. Renz BE, Vygantas CM. Hyaloid vascular remnants in human neonates. *Ann Ophthalmol* 1977; 9:179-84. [PMID: 843019]
68. Jousen AM, Beecken WD, Moromizato Y, Schwartz A, Kirchhof B, Poulaki V. Inhibition of inflammatory corneal angiogenesis by TNP-470. *Invest Ophthalmol Vis Sci* 2001; 42:2510-6. [PMID: 11581191]
69. Cretton-Scott E, Placidi L, McClure H, Anderson DC, Sommadossi JP. Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys. *Cancer Chemother Pharmacol* 1996; 38:117-22. [PMID: 8616900]
70. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *J Cell Biol* 2003; 161:1163-77. [PMID: 12810700]
71. Gogat K, Le Gat L, Van Den Berghe L, Marchant D, Kobetz A, Gadin S, Gasser B, Quere I, Abitbol M, Menasche M. VEGF and KDR gene expression during human embryonic and fetal eye development. *Invest Ophthalmol Vis Sci* 2004; 45:7-14. [PMID: 14691147]
72. Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, Dvorak AM, Dvorak HF, Puder M, Mukhopadhyay D, Folkman J. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. *Cancer Cell* 2005; 7:251-61. [PMID: 15766663]
73. Wang YQ, Luk JM, Chu AC, Ikeda K, Man K, Kaneda K, Fan ST. TNP-470 blockage of VEGF synthesis is dependent on MAPK/COX-2 signaling pathway in PDGF-BB-activated hepatic stellate cells. *Biochem Biophys Res Commun* 2006; 341:239-44. [PMID: 16413500]
74. Emoto M, Ishiguro M, Iwasaki H, Kikuchi M, Kawarabayashi T. TNP-470 inhibits growth and the production of vascular endothelial growth factor of uterine carcinosarcoma cells in vitro. *Anticancer Res* 2000; 20:601-4. [PMID: 10769702]
75. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, Harada T, Ozono Y, Koji T, Kohno S. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. *Kidney Int* 2004; 66:1677-85. [PMID: 15458466]
76. Yang H, Xu Z, Iuvone PM, Grossniklaus HE. Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) to pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model. *Mol Vis* 2006; 12:511-7. [PMID: 16735992]
77. De S, Razorenova O, McCabe NP, O'Toole T, Qin J, Byzova TV. VEGF-integrin interplay controls tumor growth and vascularization. *Proc Natl Acad Sci USA* 2005; 102:7589-94. [PMID: 15897451]
78. Sima J, Zhang SX, Shao C, Fant J, Ma JX. The effect of angiostatin on vascular leakage and VEGF expression in rat retina. *FEBS Lett* 2004; 564:19-23. [PMID: 15094037]
79. Drixler TA, Borel Rinkes IH, Ritchie ED, Treffers FW, van Vroonhoven TJ, Gebbink MF, Voest EE. Angiostatin inhibits pathological but not physiological retinal angiogenesis. *Invest Ophthalmol Vis Sci* 2001; 42:3325-30. [PMID: 11726640]
80. te Velde EA, Kusters B, Maass C, de Waal R, Borel Rinkes IH. Histological analysis of defective colonic healing as a result of angiostatin treatment. *Exp Mol Pathol* 2003; 75:119-23. [PMID: 14516772]
81. Matsunaga T, Weihrauch DW, Moniz MC, Tessmer J, Warltier DC, Chilian WM. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. *Circulation* 2002; 105:2185-91. [PMID: 11994253]

82. Parentin F, Tonini G, Perissutti P. Refractive evaluation in children with growth defect. *Curr Eye Res* 2004; 28:11-5. [PMID: 14704909]
83. Hellstrom A, Hard AL, Svensson E, Niklasson A. Ocular fundus abnormalities in children born before 29 weeks of gestation: a population-based study. *Eye* 2000; 14:324-9. [PMID: 11026993]
84. Hellstrom A, Svensson E, Carlsson B, Niklasson A, Albertsson-Wikland K. Reduced retinal vascularization in children with growth hormone deficiency. *J Clin Endocrinol Metab* 1999; 84:795-8. [PMID: 10022455]
85. Hellstrom A, Carlsson B, Niklasson A, Segnestam K, Boguszewski M, de Lacerda L, Savage M, svensson E, Smith L, Weinberger D, Albertsson Wikland K, Laron Z. IGF-I is critical for normal vascularization of the human retina. *J Clin Endocrinol Metab* 2002; 87:3413-6. [PMID: 12107259]
86. Igarashi T, Miyake K, Kato K, Watanabe A, Ishizaki M, Ohara K, Shimada T. Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. *Gene Ther* 2003; 10:219-26. [PMID: 12571629]
87. Sima J, Ma J, Zhang SX, Guo J. Study of the influence of angiostatin intravitreal injection on vascular leakage in retina and iris of the experimental diabetic rats. *Yan Ke Xue Bao* 2006; 22:252-8. [PMID: 17378159]
88. Klein SA, Bond SJ, Gupta SC, Yacoub OA, Anderson GL. Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. *J Surg Res* 1999; 82:268-74. [PMID: 10090839]